-
Joint Prevention and Control Mechanism of the State Council: Notice on Further Optimizing the Implementation of New Crown Pneumonia Epidemic Prevention and Control Measures
Time of Update: 2023-01-01
Screenshot of web pagesNotice on further optimizing the implementation of the prevention and control measures of the new crown pneumonia epidemicNotice on further optimizing the implementation of the
-
Heavy! Three domestic new crown vaccines were included in emergency use
Time of Update: 2023-01-01
SCTV01C is a new generation of 2-valent variant recombinant protein vaccine independently developed by China Cell Engineering for the problems of rapid mutation of new coronavirus and the decline of neutralizing antibody titer and protection rate of variant neutralizing antibodies based on the original strain, and is clinically intended to be used to prevent diseases caused by novel coronavirus infection (COVID-19).
-
What is the origin of the $5 billion summit to buy AK112?
Time of Update: 2023-01-01
Duggan, a strong believer in the value of irutinib, continued to invest to become Pharmacyclics' largest shareholder (20% in a cumulative investment of $43 million) and became CEO himself in 2008.
-
Pfizer rare disease revenue of $3.5 billion, future bet on gene therapy
Time of Update: 2023-01-01
The future bets on gene therapyThe future bets on gene therapyToday, Pfizer is working to lay out a new generation of breakthrough therapies, including several models: small molecules, large molecules/monoclonal antibodies (mAbs), gene therapies, and even devices, hoping to regain a high ground in the field of rare diseases through potential new therapies, and the current standard of treatment is far from sufficient for the population of patients with multiple rare diseases.
-
The revenue is comparable to Hengrui, the market value is quite Baekje, and the well-known Biotech was snapped up by Johnson & Johnson, Sanofi, and Amgen, what enlightenment does it bring to China's Biotech?
Time of Update: 2023-01-01
The company has created a Hengrui revenue volume with a market value equivalent to Baekje, listed 1 blockbuster and 1 potential blockbuster in 14 years, and successfully transformed from Biotech to Biopharma.
-
Bloomberg: Novartis may acquire GSK
Time of Update: 2023-01-01
According to Bloomberg, London-based stock research firm Intron Health reported that Novartis is considering a major acquisition, and GlaxoSmithKline (GSK) could be a potential acquisition target.
According to Bloomberg, London-based stock research firm Intron Health reported that Novartis is considering a major acquisition, and GlaxoSmithKline (GSK) could be a potential acquisition target.
-
Looking forward to pharmaceutical research innovation, hoping that drugs will cure the "new crown"
Time of Update: 2023-01-01
Promote drug research and development, more cutting-edge technologies are put into use, and intelligent simplification of complex data screening,Looking forward to "tomorrow", no matter how severe the epidemic is, it will also be defeated by the hands of mediciners, so that society will no longer talk about the "crown" color change, and let people live freely and happily.
-
More than 10 new deals in November! Involving Sanofi, Henlius, Simcere Pharmaceutical, Biocytogen, etc
Time of Update: 2023-01-01
In November 2022, the activity of licensing in and outside of local enterprises and between domestic enterprises recovered compared with October. According to GBI The SOURCE database global trading se
-
Forbes' "30 under 30" list is out, what changes are these young talents expected to bring to the healthcare field?
Time of Update: 2023-01-01
Arise hopes to improve access to eating disorder treatment through virtual care pathways, community support, and moreOriginal: _mstmutation="1" _msthash="220780" _msttexthash="11953110"> Image source: Curi Bio's official websiteMr. Elliot Fisher is the co-founder of Curi Bio. Curi Bio aims to use stem cell technology to develop organ-on-a-chip models of human heart and muscle tissue to test new drugs, and has built an AI-based data analysis platform.
-
FDA updates draft facility communication guidance for pre-filing applications for priority review of generic drugs
Time of Update: 2023-01-01
The guide also includes a Q&A section that addresses questions about PFC FAQs. The US FDA was released on December 2 Draft guidance entitled "ANDA: Pre-Nomination Facility Communication Related to Priority Generic Drug Submissions" was released, containing generic program enhancements related to the content, timing and evaluation of Pre-Nomination Facility Communications (PFC) in the Simplified New Drug Application (ANDA) review program, which is the Generic User Fee Amendment Reauthorization (GDUFA).
-
Layoffs, selling pipelines, selling factories, selling companies... 2022 Global Health Enterprise "Cash Stockpile Winter"
Time of Update: 2023-01-01
On November 9, Siemens Healthineers downsized and reorganized its In Vitro Diagnostics business unitThis streamlining aims to bring some older systems out of the market sooner (or around 50 percent) than previously planned after the introduction of its Atellica lab system, in order to simplify the product portfolio and focus on the core pipeline.
-
Works in 10 minutes! The world's first new drug for dry eye syndrome was declared for marketing, and the market war ignited?
Time of Update: 2023-01-01
How are dry eye medications going?How are dry eye medications going?At present, in addition to the marketing application submitted by Reproxalap, there are several models that are in the clinical phase 3 stage to look forward to: timbetasin timbetasintimbetasin was developed by RegeneRx to treat dry eyes.
-
Why is there a dilemma in formulating a medical insurance catalogue? ——Reflections triggered by the principal-agent relationship
Time of Update: 2023-01-01
"Strategic purchase" of medical insurance: the "only magic weapon" to hold the bottom line of people's livelihood protection In this complex multi-agency relationship, two major factors directly affect the effectiveness and efficiency of the agent, on the one hand, whether the goal pursued by the agent and the principal is the same, and on the other hand, whether the information between the agent and the principal is smooth.
-
Taking stock of 26 emerging protein degradation companies, what innovative trends do they reveal?
Time of Update: 2023-01-01
In the 20 years since the publication of the first PROTAC molecule, this technology has been transformed from academia into preclinical and clinical new drug development projects, and in 2019, it firs
-
2022 license-out! The new drugs developed by more than 10 Chinese companies have successfully achieved overseas authorization!
Time of Update: 2023-01-01
2022 is coming to an end. In the field of innovative drug research and development, under the general trend of global cooperation, the licensing cooperation in the field of innovative drugs in China w
-
The demand for domestic antigen reagents has increased greatly, but the profit margin is limited, and the US antigen market price is still high
Time of Update: 2023-01-01
With the optimization and adjustment of epidemic prevention policies, antigen testing has become an important detection method, antigen reagents are selling hot again, and enterprises have increased p
-
3 new crown vaccines approved on the same day! Wantai, Clover... 12 models have been approved in China
Time of Update: 2023-01-01
Domestic participation in the research and development of phase III and II/III phase new crown oral drugs Screenshot from: Insight database In the afternoon, Wantai Biotech announced that its nasal spray virus vector new crown vaccine was approved for emergency use.
-
Professor Li Jie: Medical ethics, using science to set up a measuring stick between people and life
Time of Update: 2023-01-01
With the development of modern medicine and the upgrading of China's medical development concept, the attributes of patients as the common carrier of human and life are increasingly valued, and at the
-
mRNA cancer vaccine presses the accelerator button, how is the progress of domestic enterprises catching up with learning?
Time of Update: 2023-01-01
"Wang Hai's team of the National Nano Center makes new breakthroughs in tumor nanovaccines", BioWorld, 2022-11-23 In fact, the three major mRNA giants BioNTech, Moderna, CureVac and some domestic mRNA companies, as early as before the development of new crown vaccines, mainly promoted therapeutic cancer vaccines as core projects of their respective mRNA technologies.
-
The price of Lianhua Qingwen has increased by 6 times! Industry insiders: There is no need to stock up on medicines, hospitals have sufficient reserves
Time of Update: 2023-01-01
"Lianhua Qingwen and ibuprofen have been sold short,In December, as various places have successively adjusted their new crown epidemic prevention policies, the sentiment of "hoarding medicine" is also quietly spreading, what is the real situation?One of the first cities to adjust was Guangzhou.
